PMID- 35845516
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220719
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 12
DP  - 2022 Jun
TI  - Clinical efficacy of endoscopic antireflux mucosectomy vs. Stretta radiofrequency 
      in the treatment of gastroesophageal reflux disease: a retrospective, 
      single-center cohort study.
PG  - 660
LID - 10.21037/atm-22-2071 [doi]
LID - 660
AB  - BACKGROUND: Currently, antireflux mucosectomy (ARMS) and Stretta radiofrequency 
      (SRF) are the most commonly used minimally invasive antireflux therapies. To 
      date, there have not been any reports comparing ARMS and SRF. Our aim was to 
      compare the clinical efficacies of these two therapeutic methods. METHODS: We 
      analyzed data from gastroesophageal reflux disease (GERD) patients, including 39 
      who received ARMS treatment and 30 who received SRF treatment between January 
      2020 and May 2021. Symptom control, gastroesophageal reflux disease questionnaire 
      (GERDQ) score, gastroesophageal reflux disease health-related quality of life 
      (GERD-HRQL) score, proton pump inhibitor (PPI) withdrawal, and PPI reduction were 
      analyzed and compared. RESULTS: After 6 months of follow-up, the results showed 
      that both therapies were effective in improving symptoms and quality of life. No 
      difference was found between the ARMS group and SRF group in GERDQ score, 
      GERD-HRQL score, PPI withdrawal rate, or PPI reduction rate (P>0.05). There was 
      no significant difference in the PPI withdrawal rate between the two therapies 
      among patients with gastroesophageal flap valve (GEFV) grade II and grade III 
      (P>0.05), but the PPI withdrawal rate in the ARMS group was significantly higher 
      than that in the SRF group among patients with GEFV grade IV (P<0.05). 
      CONCLUSIONS: The clinical efficacies of ARMS and SRF 6 months postoperation were 
      equivalent. The results showed that both ARMS and SRF treatment were acceptable 
      for patients with GEFV grades II and III, while ARMS should be selected for 
      patients with GEFV grade IV.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Sui, Xinke
AU  - Sui X
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Gao, Xiaopei
AU  - Gao X
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Zhang, Lu
AU  - Zhang L
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Zhong, Changqing
AU  - Zhong C
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Chen, Yan
AU  - Chen Y
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Wang, Xiaoying
AU  - Wang X
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Li, Dou
AU  - Li D
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Wu, Wei
AU  - Wu W
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Strategic Support Force 
      Medical Center, Beijing, China.
FAU - Li, Lianyong
AU  - Li L
AD  - Department of Gastroenterology, Strategic Support Force Medical Center, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9279761
OTO - NOTNLM
OT  - Antireflux mucosectomy (ARMS)
OT  - Stretta radiofrequency (SRF)
OT  - clinical efficacy
OT  - gastroesophageal reflux disease (GERD)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-2071/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/19 06:01
PMCR- 2022/06/01
CRDT- 2022/07/18 03:50
PHST- 2022/03/25 00:00 [received]
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/07/18 03:50 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/19 06:01 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - atm-10-12-660 [pii]
AID - 10.21037/atm-22-2071 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Jun;10(12):660. doi: 10.21037/atm-22-2071.